An article published in The Lancet Neurologyrecommends a phase III study for the drug tarenflurbil, amedication given to patients with mild Alzheimer's disease (AD). Thephase II study found that patients who took 800 mg of tarenflurbiltwice daily had better functional ability results than patients takingplacebo.